Earlier antiretroviral therapy (ART) to maintain a high level CD4 cell count may reduce HIV-associated neurocognitive disorder (HAND) prevalence and severity.
Why this matters
HIV-associated neurocognitive disorder (HAND) is highly prevalent globally in adults, especially in sub-Saharan Africa and Latin America, and in those with a high level of nadir CD4 count.
Understanding the prevalence and demographic factors contributing to HAND will allow for improved detection and more efficient management of the condition.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.